🍽️ isocarboxazid,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antidepressant Effect: Isocarboxazid is used to alleviate symptoms of depression, including persistent sadness, loss of interest or pleasure in activities, changes in appetite or weight, sleep disturbances, fatigue, feelings of worthlessness or guilt, difficulty concentrating, and thoughts of death or suicide. By inhibiting the enzyme monoamine oxidase, isocarboxazid increases the levels of neurotransmitters such as serotonin, dopamine, and norepinephrine in the brain, which are believed to play a role in regulating mood.

  2. Treatment-Resistant Depression: Isocarboxazid is particularly useful in cases of treatment-resistant depression, where other antidepressant medications have not been effective. It may be prescribed when other classes of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), have failed to produce satisfactory results.

  3. Symptom Improvement: Patients typically experience a gradual improvement in depressive symptoms with isocarboxazid treatment. It may take several weeks for the full therapeutic effect to be realized. It is important for patients to continue taking the medication as prescribed, even if they start to feel better, to prevent a relapse of depression.

  4. Side Effects: Isocarboxazid can cause various side effects, including dizziness, drowsiness, blurred vision, dry mouth, constipation, urinary retention, orthostatic hypotension (a sudden drop in blood pressure upon standing), weight gain, sexual dysfunction, and insomnia. Some individuals may also experience hypertensive crisis, a potentially life-threatening condition characterized by severe headache, palpitations, chest pain, nausea, vomiting, sweating, and a rapid increase in blood pressure, especially if they consume foods or beverages high in tyramine while taking isocarboxazid.

  5. Dietary Restrictions: Due to the risk of hypertensive crisis, patients taking isocarboxazid must adhere to a strict dietary regimen that avoids foods and beverages containing high levels of tyramine, a compound found in aged, fermented, or spoiled foods. These include aged cheeses, cured meats, pickled or fermented foods, certain alcoholic beverages (especially beer and red wine), and some types of beans and nuts. Consuming these foods while taking isocarboxazid can lead to a sudden and dangerous increase in blood pressure.

  6. Drug Interactions: Isocarboxazid can interact with a variety of medications and substances, including other antidepressants, certain pain medications (e.g., opioids), stimulants, decongestants, sympathomimetic agents, and certain herbal supplements. These interactions can potentiate the effects of isocarboxazid or other medications, leading to serious adverse reactions such as serotonin syndrome or hypertensive crisis.

  7. Contraindications: Isocarboxazid is contraindicated in individuals with a history of hypersensitivity to the medication, severe liver disease, pheochromocytoma (a rare tumor of the adrenal glands), congestive heart failure, or a recent history of myocardial infarction. It should not be used concurrently with other MAOIs or within 14 days of discontinuing treatment with other MAOIs.

  8. Monitoring: Patients taking isocarboxazid require regular monitoring of their blood pressure, especially during the initial weeks of treatment and following any dosage adjustments. Blood pressure should also be monitored if the patient experiences symptoms suggestive of hypertensive crisis.

  9. Gradual Discontinuation: Discontinuing isocarboxazid should be done gradually under the supervision of a healthcare professional to minimize the risk of withdrawal symptoms or recurrence of depression.

  10. Patient Education: Patients prescribed isocarboxazid should be educated about the importance of adhering to dietary restrictions, avoiding interactions with other medications or substances, monitoring for side effects, and seeking medical attention if they experience any concerning symptoms.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of isocarboxazid,(prescription) On Probiotics

Rank Probiotic Impact
species Bacteroides uniformis Reduces
species Escherichia coli Reduces

Bacteria Impacted by isocarboxazid,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Escherichia genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Bacteroides genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Lacrimispora genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Escherichia coli O25:H16 no rank Decreases 👶 Source Study
Escherichia coli O145:H34 no rank Decreases 👶 Source Study
Escherichia coli O16:H48 no rank Decreases 👶 Source Study
Escherichia coli O141:H4 no rank Decreases 👶 Source Study
Escherichia coli O139:H1 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Escherichia coli O158:H23 no rank Decreases 👶 Source Study
Escherichia coli O84:H7 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H4 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O78:H51 no rank Decreases 👶 Source Study
Escherichia coli O18ac:H14 no rank Decreases 👶 Source Study
Escherichia coli O85:H1 no rank Decreases 👶 Source Study
Escherichia coli O7:H15 no rank Decreases 👶 Source Study
Escherichia coli O68:H12 no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O1:K1:H7 no rank Decreases 👶 Source Study
Escherichia coli O15:H12 no rank Decreases 👶 Source Study
Escherichia coli O170:H18 no rank Decreases 👶 Source Study
Escherichia coli O155:H21 no rank Decreases 👶 Source Study
Escherichia coli O19:H7 no rank Decreases 👶 Source Study
Escherichia coli O2:K1:H5 no rank Decreases 👶 Source Study
Escherichia coli O20:H12 no rank Decreases 👶 Source Study
Escherichia coli O111 serogroup Decreases 👶 Source Study
Escherichia coli O121 serogroup Decreases 👶 Source Study
Escherichia coli O155 serogroup Decreases 👶 Source Study
Escherichia coli O177 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O3 serogroup Decreases 👶 Source Study
Escherichia coli O5 serogroup Decreases 👶 Source Study
Escherichia coli O86 serogroup Decreases 👶 Source Study
Escherichia coli O91 serogroup Decreases 👶 Source Study
Escherichia coli O103 serogroup Decreases 👶 Source Study
Escherichia coli O78 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O119 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O1:HNT serotype Decreases 👶 Source Study
Escherichia coli O10:K5(L):H4 serotype Decreases 👶 Source Study
Escherichia coli O103:H11 serotype Decreases 👶 Source Study
Escherichia coli O103:H25 serotype Decreases 👶 Source Study
Escherichia coli O104:H21 serotype Decreases 👶 Source Study
Escherichia coli O111:H11 serotype Decreases 👶 Source Study
Escherichia coli O111:H8 serotype Decreases 👶 Source Study
Escherichia coli O112ac:H19 serotype Decreases 👶 Source Study
Escherichia coli O114:H49 serotype Decreases 👶 Source Study
Escherichia coli O118:H16 serotype Decreases 👶 Source Study
Escherichia coli O121:H7 serotype Decreases 👶 Source Study
Escherichia coli O123:H11 serotype Decreases 👶 Source Study
Escherichia coli O127:H27 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O128:H2 serotype Decreases 👶 Source Study
Escherichia coli O128ac:H12 serotype Decreases 👶 Source Study
Escherichia coli O145:H25 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O146:H21 serotype Decreases 👶 Source Study
Escherichia coli O153:H2 serotype Decreases 👶 Source Study
Escherichia coli O156:H25 serotype Decreases 👶 Source Study
Escherichia coli O157:H43 serotype Decreases 👶 Source Study
Escherichia coli O157:NM serotype Decreases 👶 Source Study
Escherichia coli O165:H25 serotype Decreases 👶 Source Study
Escherichia coli O174:H2 serotype Decreases 👶 Source Study
Escherichia coli O174:H21 serotype Decreases 👶 Source Study
Escherichia coli O174:H8 serotype Decreases 👶 Source Study
Escherichia coli O176:H45 serotype Decreases 👶 Source Study
Escherichia coli O177:NM serotype Decreases 👶 Source Study
Escherichia coli O26:H1 serotype Decreases 👶 Source Study
Escherichia coli O28ac:NM serotype Decreases 👶 Source Study
Escherichia coli O29:H4 serotype Decreases 👶 Source Study
Escherichia coli O32:H37 serotype Decreases 👶 Source Study
Escherichia coli O6:H16:CFA/II serotype Decreases 👶 Source Study
Escherichia coli O69:H11 serotype Decreases 👶 Source Study
Escherichia coli O78:H12 serotype Decreases 👶 Source Study
Escherichia coli O79:H7 serotype Decreases 👶 Source Study
Escherichia coli O81:NM serotype Decreases 👶 Source Study
Escherichia coli O86:H34 serotype Decreases 👶 Source Study
Escherichia coli O91:H14 serotype Decreases 👶 Source Study
Escherichia coli O91:NM serotype Decreases 👶 Source Study
Escherichia coli ONT:H33 serotype Decreases 👶 Source Study
Escherichia coli O100:H21 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O16:H6 serotype Decreases 👶 Source Study
Escherichia coli O89m:H9 serotype Decreases 👶 Source Study
Escherichia coli O111:H- serotype Decreases 👶 Source Study
Escherichia coli O113:H21 serotype Decreases 👶 Source Study
Escherichia coli H20 serotype Decreases 👶 Source Study
Escherichia coli O150:H6 serotype Decreases 👶 Source Study
Escherichia coli O111:NM serotype Decreases 👶 Source Study
Escherichia coli O112ab:H8 serotype Decreases 👶 Source Study
Escherichia coli O99:H6 serotype Decreases 👶 Source Study
Escherichia coli O26:H11 serotype Decreases 👶 Source Study
Escherichia coli O145:H28 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O2:H6 serotype Decreases 👶 Source Study
Escherichia coli O7:H4 serotype Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O25:NM serotype Decreases 👶 Source Study
Escherichia coli O25:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O125ac:K+:H10 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O152:H23 serotype Decreases 👶 Source Study
Escherichia coli O15:H18 serotype Decreases 👶 Source Study
Escherichia coli O39:NM serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O2:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O8:H8 serotype Decreases 👶 Source Study
Escherichia coli O89m:H10 serotype Decreases 👶 Source Study
Escherichia coli O10:H32 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O157:H- serotype Decreases 👶 Source Study
Escherichia coli O45:H2 serotype Decreases 👶 Source Study
Escherichia coli O103:H2 serotype Decreases 👶 Source Study
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O83:H1 serotype Decreases 👶 Source Study
Escherichia coli O9:H10 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Bilophila wadsworthia species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Roseburia intestinalis species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study

Impact of isocarboxazid,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.3 0.3
ADHD 1.6 1.6
Age-Related Macular Degeneration and Glaucoma 0.5 0.4 0.25
Allergic Rhinitis (Hay Fever) 1.6 0.5 2.2
Allergies 1.7 0.6 1.83
Allergy to milk products 0.5 1.3 -1.6
Alzheimer's disease 2.4 2.2 0.09
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.8 0.3 1.67
Ankylosing spondylitis 1.4 0.6 1.33
Anorexia Nervosa 0.7 1.3 -0.86
Antiphospholipid syndrome (APS) 0.7 0.3 1.33
Asthma 2.3 1.1 1.09
Atherosclerosis 1 0.6 0.67
Atrial fibrillation 1.2 1.6 -0.33
Autism 2.6 3.1 -0.19
Autoimmune Disease 0.9 0.5 0.8
Barrett esophagus cancer 0.3 0.3 0
benign prostatic hyperplasia 0.6 0.3 1
Biofilm 0.8 0.8
Bipolar Disorder 1.6 0.5 2.2
Brain Trauma 0.3 0.8 -1.67
Breast Cancer 0.5 0.5
Cancer (General) 0.3 0.3
Carcinoma 2.5 0.7 2.57
Celiac Disease 1.1 1 0.1
Cerebral Palsy 0.6 0.8 -0.33
Chronic Fatigue Syndrome 1.2 1 0.2
Chronic Kidney Disease 1.3 0.8 0.63
Chronic Lyme 0.8 -0.8
Chronic Obstructive Pulmonary Disease (COPD) 1.3 1.1 0.18
Chronic Urticaria (Hives) 1.1 0.2 4.5
Coagulation / Micro clot triggering bacteria 1.6 0.8 1
Cognitive Function 1 0.8 0.25
Colorectal Cancer 3.6 1.1 2.27
Constipation 0.9 0.5 0.8
Coronary artery disease 1.1 1 0.1
COVID-19 2.4 1.7 0.41
Crohn's Disease 3.4 1.7 1
Cushing's Syndrome (hypercortisolism) 0.3 -0.3
cystic fibrosis 0.9 0.8 0.13
d-lactic acidosis (one form of brain fog) 0.3 0.3
deep vein thrombosis 1.3 1.1 0.18
Denture Wearers Oral Shifts 1 1
Depression 3.2 2.4 0.33
Dermatomyositis 0.3 0.3
Eczema 1.2 0.9 0.33
Endometriosis 1.9 0.8 1.37
Eosinophilic Esophagitis 0.3 0.3 0
Epilepsy 1.9 0.9 1.11
erectile dysfunction 1.2 1.2
Fibromyalgia 1.2 0.3 3
Functional constipation / chronic idiopathic constipation 2.1 1.4 0.5
gallstone disease (gsd) 1.4 0.8 0.75
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.7 0.3 1.33
Generalized anxiety disorder 1.7 0.6 1.83
Glioblastoma 0.3 -0.3
Gout 0.6 0.6
Graves' disease 0.7 1.1 -0.57
Gulf War Syndrome 0.3 0.2 0.5
Halitosis 1.1 0.3 2.67
Hashimoto's thyroiditis 1.3 0.6 1.17
Heart Failure 2.1 0.5 3.2
hemorrhagic stroke 0.7 0.7
Hidradenitis Suppurativa 1.2 1.2
High Histamine/low DAO 0.8 0.8
hypercholesterolemia (High Cholesterol) 0.3 0.3
hyperglycemia 1.3 0.7 0.86
Hyperlipidemia (High Blood Fats) 0.3 0.3
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 1.8 1.6 0.13
Hypoxia 1.6 1.6
IgA nephropathy (IgAN) 1.3 0.6 1.17
Inflammatory Bowel Disease 3.1 2.1 0.48
Insomnia 1.1 1.1 0
Intelligence 0.6 0.6
Intracranial aneurysms 1 1
Irritable Bowel Syndrome 2.4 1.6 0.5
ischemic stroke 1.3 1.4 -0.08
Liver Cirrhosis 3.6 2 0.8
Long COVID 1.9 1.8 0.06
Low bone mineral density 0.5 -0.5
Lung Cancer 0.9 0.9
Lymphoma 0.6 0.6
Mast Cell Issues / mastitis 1.2 1.2
ME/CFS with IBS 0.3 0.3 0
ME/CFS without IBS 0.3 0.3 0
membranous nephropathy 0.3 0.3
Menopause 0.3 0.5 -0.67
Metabolic Syndrome 3.3 2.3 0.43
Mood Disorders 2.9 2.3 0.26
multiple chemical sensitivity [MCS] 0.8 0.8
Multiple Sclerosis 2.4 1.7 0.41
myasthenia gravis 0.9 0.5 0.8
neuropathic pain 1.3 -1.3
Neuropathy (all types) 0.3 1.6 -4.33
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.3 0.8 1.87
NonCeliac Gluten Sensitivity 0.3 0.3 0
Obesity 3 2.8 0.07
obsessive-compulsive disorder 2 0.6 2.33
Osteoarthritis 1.2 0.6 1
Osteoporosis 1.4 0.6 1.33
pancreatic cancer 0.6 0.3 1
Parkinson's Disease 3.3 2.3 0.43
Polycystic ovary syndrome 2.8 1.4 1
Premenstrual dysphoric disorder 0.4 -0.4
primary biliary cholangitis 0.3 0.6 -1
Primary sclerosing cholangitis 1.3 0.4 2.25
Psoriasis 0.7 1.3 -0.86
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.7 1.3 1.08
Rosacea 0.5 -0.5
Schizophrenia 1.6 1.3 0.23
scoliosis 0.3 0.3 0
Sjögren syndrome 1.3 0.7 0.86
Sleep Apnea 0.3 0.8 -1.67
Slow gastric motility / Gastroparesis 0.5 0.5
Small Intestinal Bacterial Overgrowth (SIBO) 1.1 1.1
Stress / posttraumatic stress disorder 1.8 1.3 0.38
Systemic Lupus Erythematosus 2.3 0.6 2.83
Tic Disorder 0.3 0.3
Tourette syndrome 0.3 0.3 0
Type 1 Diabetes 1.6 1.1 0.45
Type 2 Diabetes 3.1 2.3 0.35
Ulcerative colitis 2.3 1.7 0.35
Unhealthy Ageing 1.6 1 0.6
Vitiligo 1.2 0.4 2

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [216.73.216 ]